SCOPUS BIOPHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0011 USD | 0.00% |
|
0.00% | -97.45% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 215.2 | 34.49 | 2.057 |
| Enterprise Value (EV) 1 | 215.7 | 26.55 | 1.932 |
| P/E ratio | -18.3 x | -1.05 x | -0.18 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -21,239,073 x | -960,664 x | -164,953 x |
| EV / FCF | -46,000,186 x | -1,825,698 x | -520,890 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | -118 x | 8.58 x | -0.31 x |
| Nbr of stocks (in thousands) | 14,503 | 21,094 | 21,094 |
| Reference price 2 | 14.84 | 1.635 | 0.0975 |
| Announcement Date | 3/29/21 | 4/15/22 | 4/14/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | -2.689 | -10.15 | -27.63 | -11.71 |
| EBIT 1 | -0.2635 | -0.686 | -2.69 | -10.16 | -27.63 | -11.71 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.2635 | -0.686 | -2.69 | -10.86 | -26.95 | -11.71 |
| Net income 1 | -0.2635 | -0.686 | -2.69 | -10.86 | -26.95 | -11.61 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0476 | -0.0649 | -0.2238 | -0.8129 | -1.562 | -0.5504 |
| Free Cash Flow | - | -0.4087 | -1.444 | -4.688 | -14.54 | -3.709 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/18/19 | 6/18/19 | 5/15/20 | 3/29/21 | 4/15/22 | 4/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 0.45 | - | - |
| Net Cash position 1 | 0.16 | 0 | 0.04 | - | 7.94 | 0.12 |
| Leverage (Debt/EBITDA) | - | - | - | -0.0445 x | - | - |
| Free Cash Flow | - | -0.41 | -1.44 | -4.69 | -14.5 | -3.71 |
| ROE (net income / shareholders' equity) | - | -1,425% | 6,101% | 1,135% | -2,466% | 770% |
| ROA (Net income/ Total Assets) | - | -248% | -372% | -462% | -340% | -171% |
| Assets 1 | - | 0.2764 | 0.7235 | 2.349 | 7.929 | 6.802 |
| Book Value Per Share 2 | 0.0100 | -0 | -0.0100 | -0.1300 | 0.1900 | -0.3100 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0 | 0.1300 | 0.3800 | 0.0100 |
| Capex | - | - | 0 | - | 0 | 0 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 6/18/19 | 6/18/19 | 5/15/20 | 3/29/21 | 4/15/22 | 4/14/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -97.45% | 46.29K | |
| -2.23% | 103B | |
| +1.76% | 95.28B | |
| +1.46% | 22.15B | |
| -15.59% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -12.74% | 16.05B | |
| +5.12% | 13.68B | |
| +35.94% | 12.17B |
- Stock Market
- Equities
- SCPS Stock
- Financials Scopus BioPharma Inc.
